


## Czech Republic

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat man



December	Change since previous	s survey: ▲ Improvement ▼ Decline	2009		2012		2015		2018
Organisation Comprehensive Care Centres (CCC's) Yes Yes Yes Yes Yes Of care Haemophilia Treatment Centres National Haemophilia Council or Co-ordinating Group Number of groups in decision-making on haemophilia care Number of groups choosing haemophilia treatment products No	International units	Factor VIII	4.92	_	4.87	<b>A</b>	6.07	<b>A</b>	6.21
of care         Haemophilia Treatment Centres         Yes         Yes <t< th=""><th>per capita</th><th>Factor IX</th><th>0.66</th><th>•</th><th>0.55</th><th>_</th><th>0.65</th><th><b>A</b></th><th>0.70</th></t<>	per capita	Factor IX	0.66	•	0.55	_	0.65	<b>A</b>	0.70
National Haemophilia Council or Co-ordinating Group Number of groups in decision-making on haemophilia care Number of groups in decision planemophilia treatment products National Tender for procurement of factor concentrates No	Organisation	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
Number of groups in decision-making on haemophilia care   Number of groups choosing haemophilia treatment products   1	of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
Number of groups choosing haemophilia treatment products No		National Haemophilia Council or Co-ordinating Group	Yes		Yes		Yes		Yes
National Tender for procurement of factor concentrates   No   No   No   No   No   No   Prestment		Number of groups in decision-making on haemophilia care	2	<b>A</b>	3	•	2	<b>A</b>	3
Treatment		Number of groups choosing haemophilia treatment products	1		1		1	<b>A</b>	2
Regimens		National Tender for procurement of factor concentrates	No		No		No		No
Treatment delivered to the patient's home Prophylaxis treatment availability Yes Yes Yes Some Children currently on prophy (%) 76-100% 76-100% 76-100% 76-100% Adults currently on prophy (%) 1-25% 1-25% 2-650% Access to ITI (% of people with inhibitors) 100% 100% 100% 100% 100% 100% 100% 100	Treatment	Home Treatment	Yes		Yes		Yes		Yes
Prophylaxis treatment availability Children currently on prophy (%) Adults currently on prophy (%) Adults currently on prophy (%) Access to IT (% of people with inhibitors) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HIV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HIV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HIV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HIV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HIV) Access to Emergency medicine and acute surgery Paediatrics Infectious disease specialists (especially HIV) Access to Emergency Paediatrics Access to Emergency Paediatrics Access to Emergency Paediatrics Access to IT (% of people with inhibitors) Access to IT (% of people with inhibitors Access to IT (% of people wit	regimens	% of people with haemophilia using home treatment	76-100%		76-100%		76-100%		76-100%
Children currently on prophy (%)		Treatment delivered to the patient's home	No		No		No		No
Adults currently on prophy (%)		Prophylaxis treatment availability	Yes		Yes	•	Some	<b>A</b>	Yes
Access to ITI (% of people with inhibitors)  Access to Emergency medicine and acute surgery  Paediatrics Infectious disease specialists (especially HIV)  Pes Yes Yes Yes Yes  Hepatology  Rheumatology  Physiotherapy  Dentistry  Otstetrics and Gynaecology  Genetics  Social and psychological support  Pain management  General surgery  Urology  Share of Expected  Bleeding Disorder  Haemophilla  Pervalence  Von Willebrand Disease  Haemophilla  Persona derived factor concentrate  Recombinant factor concentrate  Recombinant factor concentrate  WWD replacement  WWD replacement  Plasma  Access to ITI (% of people with inhibitors)  100%  100%  100%  100%  100%  Yes  Yes  Yes  Yes  Yes  Yes  Yes  Ye		Children currently on prophy (%)	76-100%		76-100%		76-100%		76-100%
Access to Emergency medicine and acute surgery pacifalist services   Paediatrics   Paes   Pae		Adults currently on prophy (%)	1-25%		1-25%	<b>A</b>	26-50%	<b>A</b>	51-75%
Paediatrics Infectious disease specialists (especially HIV)		Access to ITI (% of people with inhibitors)	100%		100%		100%		100%
Infectious disease specialists (especially HIV) Hepatology Rheumatology Rheumatology Pes Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Haemophilia B Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate VYD replacement Plasma Infectious disease specialists (especially HIV) Yes	Access to	Emergency medicine and acute surgery	Yes		Yes		Yes		Yes
Hepatology Rheumatology Orthopaedics Orthopaedics Physiotherapy Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate Cryoprecipitate Ves Ves Ves Ves Ves Ves Ves Ves Ves Ve	specialist services	Paediatrics	Yes		Yes		Yes		Yes
Rheumatology Orthopaedics Physiotherapy Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Prevalence Haemophilia Pasma-derived factor concentrate Herapy Plasma Pl		Infectious disease specialists (especially HIV)	Yes		Yes		Yes		Yes
Orthopaedics Physiotherapy Dentistry Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urrology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate VWD replacement Plasma DDAVP Plasma  Orthopaedics Yes Sometimes Yes Yes Yes Yes Yes Yes Yes Yes Yes Y		Hepatology	Yes		Yes		Yes		Yes
Physiotherapy Dentistry Dentistry Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Prevalence Von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombiant factor concentrate Recombiant factor concentrate Rarely Plasma PDAVP Plasma  Pes  Yes Yes Yes Yes Yes Yes Yes Yes Yes		Rheumatology	Yes	•	Sometimes	<b>A</b>	Yes		Yes
Dentistry Obstetrics and Gynaecology Genetics Genetics Social and psychological support Pain management General surgery Urology Share of Expected Bleeding Disorder Haemophilia A Bleeding Disorder Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Recombinant factor concentrate Cryoprecipitate  WWD replacement Plasma Persulacer  Plasma Persulacer  Plasma Plasma-derived factor concentrate Recombinant factor concentrate Rarely Plasma Plasma Plasma Plasma Plasma-derived factor concentrate Rarely Plasma Plasma Plasma-derived factor concentrate Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Rarely Plasma Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Plasma-derived factor concentrate Rarely Plasma Never		Orthopaedics	Yes		Yes		Yes		Yes
Obstetrics and Gynaecology Genetics Social and psychological support Pain management General surgery Urology Share of Expected Haemophilia A Haemophilia B Perevalence Haemophilia Pasma-derived factor concentrate Recombinant factor concentrate Cryop replacement Cryop replacement CDAVP Plasma  Pres  Yes Yes Yes Yes Yes Yes Yes Yes Yes		Physiotherapy	Sometimes	<b>A</b>	Yes		Yes		Yes
Genetics Social and psychological support Pain management General surgery Urology Ves		Dentistry	Yes		Yes		Yes		Yes
Social and psychological support Pain management General surgery Urology Yes Vometimes Sometimes		Obstetrics and Gynaecology	Yes		Yes		Yes		Yes
Pain management General surgery Urology Yes		Genetics	Yes		Yes		Yes		Yes
General surgery Urology Yes		Social and psychological support	Sometimes	<b>A</b>	Yes	•	Sometimes		Sometimes
Urology  Yes Yes Yes Yes Yes Yes Yes Share of Expected Haemophilia A Bleeding Disorder Haemophilia B Haemophilia B Prevalence von Willebrand Disease Haemophilia Pasma-derived factor concentrate Recombinant factor fa		Pain management	Sometimes		Sometimes		Sometimes		Sometimes
Share of Expected Haemophilia A 70%		General surgery	Yes	▼	Sometimes	<b>A</b>	Yes		Yes
Bleeding Disorder Prevalence		Urology	Yes		Yes		Yes		Yes
Prevalence von Willebrand Disease  Haemophilia Pasma-derived factor concentrate Always	Share of Expected	Haemophilia A	70%	•	57%	<b>A</b>	88%	•	88%
Haemophilia Pasma-derived factor concentrate Always Always Always Always replacement Recombinant factor concentrate Rarely Rarely Always Always Always Always therapy Plasma Never	Bleeding Disorder	Haemophilia B	36%	<b>A</b>	42%	<b>A</b>	43%	<b>A</b>	43%
replacement Recombinant factor concentrate Rarely Rarely Always Always therapy Plasma Never Neve	Prevalence	von Willebrand Disease			5%	<b>A</b>	7%	<b>A</b>	8%
therapy Plasma Never Nev	Haemophilia	Pasma-derived factor concentrate	Always		Always		Always		Always
Cryoprecipitate     Never     Never     Never       VWD replacement     Plasma-derived factor concentrate     Always     Always     Always       therapy     DDAVP     Rarely     Always     Never     Rarely       Plasma     Never     Never     Never     Never	replacement	Recombinant factor concentrate	Rarely		Rarely	<b>A</b>	Always		Always
VWD replacement       Plasma-derived factor concentrate       Always       Always       Always       Always       Always         therapy       DDAVP       Rarely       ▲ Always       ▼ Never	therapy	Plasma	Never		Never		Never		Never
therapy DDAVP Rarely Always V Never A Rarely Plasma Never Never Never Never Never Never		Cryoprecipitate	Never		Never		Never		Never
Plasma Never Never Never Never Never	VWD replacement	Plasma-derived factor concentrate	Always		Always		Always		Always
	therapy	DDAVP	Rarely	<b>A</b>	Always	•	Never	<b>A</b>	Rarely
Cryoprocipitato Novas Novas Novas		Plasma	Never		Never		Never		Never
Gryophedipitate never never Never Never Never Never		Cryoprecipitate	Never		Never		Never		Never